Staphylococcus aureus is a leading cause of bacterial infections in hospitals and communities worldwide. With the development of typing methods, several pandemic clones have been well characterized, including the extensively spreading hospital-associated meticillin-resistant S. aureus (HA-MRSA) clone ST239 and the emerging hypervirulent community-associated (CA) MRSA clone USA300. The multilocus sequence typing method was set up based on seven housekeeping genes; S. aureus groups were defined by the sharing of alleles at $5 of the seven loci. In many cases, the predicted founder of a group would also be the most prevalent ST within the group. As a predicted founder of major S. aureus groups, approximately 90 % of ST121 strains was meticillin-susceptible S. aureus (MSSA). The majority of ST121 strains carry accessory gene regulator type IV, whereas staphylococcal protein A gene types for ST121 are exceptionally diverse. More than 90 % of S. aureus ST121 strains have Panton-Valentine leukocidin; other enterotoxins, haemolysins, leukocidins and exfoliative toxins also contribute to the high virulence of ST121 strains. Patients suffering from S. aureus ST121 infections often need longer hospitalization and prolonged antimicrobial therapy. In this review, we tried to summarize the epidemiology of the S. aureus clone ST121 and focused on the molecular types, toxin carriage and disease spectrum of this globally disseminated clone.
Introduction
Since its discovery by Dr Alexander Ogston in 1880, Staphylococcus aureus has been recognized as a versatile micro-organism worldwide (Ogston, 1881; Diekema et al., 2001) . S. aureus may colonize the human body as a part of the normal flora. Approximately 30 % of healthy people are inhabited by S. aureus, mostly in the anterior nares (Akmatov et al., 2014) . S. aureus is also a leading cause of hospital-associated (HA) and community-associated (CA) bacterial infections in humans, associating with numerous mild skin and soft tissue infections, as well as life-threatening pneumonia, bacteraemia, osteomyelitis, endocarditis, sepsis and toxic shock syndrome (David & Daum, 2010) . The increasing prevalence of meticillinresistant S. aureus (MRSA) and its ability to resist multiple drugs has posed a serious challenge for infection control (Junie et al., 2014) . HA-MRSA often infects individuals with health care risk factors, such as surgery or residence in a long-term care facility. By contrast, many CA-MRSA and meticillin-susceptible S. aureus (MSSA) often infect healthy persons who do not have such risk factors (Tokajian, 2014) . However, whether some S. aureus clones circulating in hospitals or communities have the ability to cause serious infections (namely hypervirulent clones) and spread internationally remains unclear.
Development of a highly discriminatory method usually benefits deep characterization and understanding of bacterial isolates. Multilocus sequence typing (MLST) methods were developed for the identification of the hypervirulent clones of Neisseria meningitidis (Maiden et al., 1998) and sorting Streptococcus pneumoniae strains to the major hypervirulent lineages (Enright & Spratt, 1998; Enright et al., 1999) . To understand the basic features of the population and evolutionary biology of S. aureus, Enright et al. (2000) developed an MLST scheme based on seven housekeeping genes (arcC, aroE, glpF, gmk, pta, tpi and yqiL) to molecularly characterize S. aureus isolates as different sequence types (STs) . Epidemiological studies have also demonstrated that the majority of S. aureus infections are caused by a small number of major clones (Rasigade et al., 2010) . For example, the major clones in the UK are EMRSA-15 (ST22) and EMRSA-16 (ST36) (Wyllie et al., 2011) , whereas the predominant clones in Japan, Hungary and the US are ST5, ST239 and ST8, respectively (Nakaminami et al., 2014; Kawaguchiya et al., 2013; Conceição et al., 2007) . Up until 8/6/2015, there were 3015 STs corresponding to 5703 S. aureus isolates collected in the MLST database (http://www.mlst.net/). These strains can be categorized into 51 groups when using five identical loci for group definition. Group 1 is the largest group, which contains 4044 isolates with 1699 STs, including ST1, ST5, ST8, ST15, ST22, ST30, ST45, ST97 and ST239, with ST5 as the predicted founder. Group 2 contains 186 isolates with 136 STs, with ST121 as the predicted founder. ST59, ST398 and ST133 are the predicted founders for Groups 3, 4 and 5, respectively (Fig. 1) .
Given that the difference in genome sequence is as high as 22 % in S. aureus (Jelsbak et al., 2010) , different clones may have variable virulence. The analysis of the global population structure and expansion of pathogenic clones of S. aureus revealed that certain clones are more virulent than others (Layer et al., 2006) . In 2007, Schefold et al. first reported a sepsis case of a 51-year-old male caused by S. aureus ST121 (Schefold et al., 2007) . We also characterized a fatal case of a 17-year-old boy with septic multiple organ failure caused by Panton-Valentine leukocidin (PVL)-positive CA-MSSA type ST121/agr IV (Rao et al., 2015) . It remains to be elucidated whether S. aureus ST121 is a globally disseminated hypervirulent clone or not. In this review, the prevalence of S. aureus ST121 in distinct geographical regions, including Africa, Asia and Europe, was summarized. The molecular types and toxin carriage of S. aureus clone ST121 were evaluated and the reported diseases caused by S. aureus clone ST121 were also discussed.
Epidemiology of S. aureus clone ST121
The epidemiology of S. aureus varies considerably on a global basis and the dominance of S. aureus clones in a certain region is geographically restricted (Tokajian, 2014 ). An investigation on the global population structure of PVL-positive MSSA revealed that the most frequent STs are ST30 (19.9 %, 42/211) and ST121 (19.9 %, 42/211) (Rasigade et al., 2010) . ST121 MSSA isolates are distributed in 15 out of the 19 surveyed countries, including Paraguay, New Caledonia, Togo, France, Czech Republic, Germany, Turkey, US, Fr. West Indies, UK, Polynesia, Switzerland, Spain, Algeria and the Netherlands. Another study that typed 292 S. aureus strains isolated from patients with uncomplicated skin infections in ten countries also demonstrated that the most common ST is ST121 (13.0 %, 38/292) (Goering et al., 2008) . However, only four ST121 S. aureus isolates (5.5 %, 4/73) were determined in a recent study with collections from 13 countries between 1961 and 2009 (Tavares et al., 2014) . The attention given to the epidemiology of a certain S. aureus clone, such as ST121, is study-orientated. Most epidemiological data relevant to the S. aureus clone ST121 are available in Africa, Asia and Europe.
Africa. The majority of infectious disease research in Africa focused on malaria, acquired immunodeficiency syndrome and tuberculosis, which are the 'big three diseases' in that area (Schaumburg et al., 2014) . Study on other infectious diseases in Africa, such as infections caused by S. aureus, has been largely neglected in the past; hence, epidemiological data on clone ST121 are scarce (Herrmann et al., 2013; Hotez et al., 2011 et al., 2014) . With the Millennium Development Goals, the picture of the spread of S. aureus, as well as certain clones (such as ST121), will be gradually uncovered despite cultural and geographical diversity in Africa.
Asia. Asia is an area with the highest prevalence of S. aureus worldwide, including HA-MRSA, CA-MRSA and MSSA (Chen & Huang, 2014) . Two pandemic HA-MRSA clones, ST239 and ST5, were reported to have disseminated internationally in Asia. However, the epidemiology of MSSA and CA-MRSA in Asia were characterized by clonal heterogeneity. Driven by the multinational surveillance programs (e.g. RSS, ANSORP and SENTRY), MRSA epidemiological data were obtained (Bell et al., 2002; Song et al., 2011) , whereas the data for certain clones remain limited. In China, where epidemiological information on S. aureus infections was largely lacking before 1998, Fan et al. (Baranovich et al., 2010) . To deeply understand the epidemiology of S. aureus clone ST121, more systematic surveillance of both hospital and community isolates is required for the countries in this region.
Molecular types of S. aureus clone ST121
Characterization of clones in a certain bacterial species is largely dependent on in-depth molecular typing. The first method for typing S. aureus is phage typing, which was introduced in 1944 by Fisk & Mordvin (Fisk & Mordvin, 1944) , followed by pulsed field gel electrophoresis (Prévost et al., 1991), spa typing (Shopsin et al., 1999) , MLST (Enright et al., 2000) and finally, staphylococcal cassette chromosome mec (SCCmec) typing (Oliveira & de Lencastre, 2002) . These methods were developed to successfully characterize S. aureus strains. No typing research specialized for S. aureus ST121 clone is available to date and the information on molecular types associated with this clone was obtained from studies with different research goals. Table 1 summarizes the available molecular data for S. aureus ST121 strain epidemic in Africa, Asia and Europe.
spa types. The spa gene product, protein A, is an important virulence factor involved in host immune system evasion for S. aureus. The repeat region of the spa was amplified by PCR and sequenced to type S. aureus strains (Harmsen et al., 2003) . The spa types of S. aureus clone ST121 geographically varied. Rasigade et al. (2010) determined the spa types of 211 PVL-positive MSSA clinical isolates collected in 19 countries throughout the world between 1981 and 2007, and revealed 11 spa types for S. aureus clone ST121, including t159, t645, t284, t435, t940, t169, t1077, t1114, t1596, t3407 and t3635. To date, 164 S. aureus ST121 isolates collected from different countries have been subjected to spa typing and a total of 26 spa types have been determined. The most common spa type for S. aureus ST121 is t159, which accounted for 35.4 % (58/164), followed by t645 (12.8 %, 21/164), t314 (11.0 %, 18/164), t2304 (6.1 %, 10/164), t916 (5.5 %, 9/164), t435 (4.9 %, 8/164), t287 (4.9 %, 8/164) and t1425 (4.3 %, 7/164) ( Table 2) . No other spa type accounted for more than 3 % of S. aureus ST121 isolates (Fig. 2a) .
A certain S. aureus ST clone usually has varied spa types, such as the globally disseminated USA300 (ST8-SCCmec IV) strains have spa types of t008, t121, t197, etc., and t008 is the dominant spa type (Seidl et al., 2014) . Among 159 ST239 and 78 ST5 MRSA strains collected in China, ST239 strains contained spa types t030, t037, t138, t459, t632 and t3167 and ST5 strains included t002, t010, t570, t2460 and t045 (Cheng et al., 2013) . The different spa types carried by one S. aureus ST clone may be helpful for tracing the strains within the ST clone, especially for the new emerging ST clones, such as ST121.
agr types. In S. aureus, the accessory gene regulator (agr) is a global regulatory system composed of two divergent transcripts, RNAII and RNAIII, which are under the control of two distinct promoters, P2 and P3 (Novick, 2003) . The P2 transcriptional unit encodes AgrB, AgrD, AgrC and AgrA. An autoinducing peptide (AIP) is produced from AgrD processed by AgrB, and secreted in the extracellular medium to bind to the AgrC transmembrane protein, which in turn, activates the AgrA response regulator. AgrA activates transcription of its own operon (P2) and RNAIII (P3). RNAIII controls the switch between early expression of surface proteins and late production of S. aureus exotoxins, playing an important role in the virulence control of S. aureus (Guillet et al., 2013) . According to the diversity of amino acid sequence and length of AgrD and AgrC, S. aureus can be divided into four agr types, namely, agr I, II, III and IV. S. aureus strains with each type of agr can lead to skin and soft tissue infections. To date, 139 S. aureus ST121 strains with agr types have been reported. Almost all S. aureus ST121 strains are agr IV (98.6 %, 137/139) ( Table 1 ). The distinctive carriage of agr IV in S. aureus ST121 strains may contribute to their characterized pathogenesis.
mecA gene carriage. The widespread use of antibiotics facilitates the emergence of multi-drug-resistant bacterial strains. MRSA may be generated from MSSA through the acquisition of SCCmec in its chromosome, which carries a mecA gene that encodes a critical determinant for meticillin resistance (Kondo et al., 2007) . The presence of the mecA gene may be simply confirmed by a PCR assay. A total of 192 S. aureus ST121 isolates were collected in literature with the information on mecA gene detection and most S. aureus ST121 strains were mecA negative (89.1 %, 171/192) (Fig. 2c) , indicating that the majority of S. aureus ST121 strains belong to MSSA.
Toxins carriage by S. aureus clone ST121
Although the toxin profiles controlled by different agr types in S. aureus need to be explored, most ST121 strains carry agr IV (Fig. 2b) . The S. aureus strains circulating in the community, such as CA-MRSA and MSSA, are believed ND, not determined. to have more toxins and are thus more virulent than HA-MRSA strains; however, HA-MRSA strains are more drug resistant than CA-MRSA and MSSA (Thurlow et al., 2012; Drebes et al., 2014) . Approximately 90 % of S. aureus ST121 strains are MSSA (Fig. 2c) . PVL is a bicomponent pore-forming cytotoxin assembled by LukS-PV and LukF-PV and closely related to the development of S. aureus infection (Hu et al., 2015) . Most MSSA strains and successful MRSA clones present high frequency of PVL carriage (Ruimy et al., 2008) . PVL carriage is a characteristic feature of CA-MRSA clones disseminated in Europe and the Middle East (ST80), Australia and South America (ST30-IV) and the United States (ST8-IV, also known as USA300) (Lina et al., 1999; Deurenberg & Stobberingh, 2009; David et al., 2011) . About 201 isolates of S. aureus ST121 are subjected to detect the lukS-lukF genes by well-characterized PCR (Severin et al., 2008) and 92.0 % (185/201) of the S. aureus ST121 isolates were PVL-positive (Fig. 2d , which can recruit polymorphonuclear cells and monocytes that play important roles in anti-staphylococcal immunity and trigger apoptosis and lysis in these cells (Kaneko & Kamio, 2004) . Although the significance of PVL in the increased virulence and pathogenicity of a certain S. aureus clone, such as USA300, is controversial (Márquez-Ortiz et al., 2014), Kreisel et al. (2011) found that 97.0 % of USA300 isolates causing bacteraemia in adult patients had PVL and suggested its role as a virulence factor. The high frequency in carriage of PVL in S. aureus ST121 strains may contribute to the hypervirulent features of the clone and favour its successful spread (Conceição et al., 2011; Rů žičková et al., 2012) .
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Except for PVL, enterotoxins (SEB, SEG, SEI, SEL), haemolysin (Hla, Hlb, Hlg, Hlg-V, Hld), leukocidins E and D (LukED) and exfoliative toxins (ETA, ETB) are involved in the infection cases caused by ST121 (Table 3) . For the exfoliative toxin-producing (ET-positive) S. aureus strains, a study conducted in one Slovak and 23 Czech maternity hospitals from 1998 to 2011 demonstrated that 37.0 % (47/127) of the isolated ET-positive strains were S. aureus ST121 (Rů žičková et al., 2012) . However, the characteristic toxin profile of S. aureus ST121 clonal strains remains unclear and needs more intensive study on strains collected globally.
Disease spectrum of S. aureus clone ST121 S. aureus often causes different diseases, and the spectrum of infections varies from mild and superficial to invasive and life-threatening diseases (Lowy, 1998) . Severe invasive infections caused by S. aureus include bacteraemia, endocarditis, pneumonia, septic arthritis and osteomyelitis, whereas the mild superficial infections mainly involve the skin or soft tissue. Table 3 summarizes the diseases related to S. aureus ST121 as one globally disseminated clone. A total of 126 cases with S. aureus ST121 infection have been reported to date. The severe invasive infections include streptodermia (1/126) (Cupane et al., 2012) , osteomyelitis (3/126) (Chheng et al., 2009; Cupane et al., 2012) , bursitis (1/126) (Cupane et al., 2012) , lymphadenitis (1/126) (Cupane et al., 2012) , cellulitis (9/126) (Conceição et al., 2011) , bacteraemia (15/126) (Holmes et al., 2005) and septic multiple organ failure (1/126) (Rao et al., 2015) ; whereas, the mild superficial infections include urinary tract infection (2/126) (González-Domínguez et al., 2012; Egyir et al., 2014) (Cupane et al., 2012) . Moreover, the clinical efficacy of the antimicrobial therapy may be insufficient for PVL-positive MSSA causing severe infections, for example, ST121 caused multiple organ failure, even though the favourable in vitro sensitivity testing of the causative S. aureus was conducted (Rao et al., 2015) . The early, combined and prolonged treatment was usually proposed for serve S. aureus ST121 infections. In the case of the first reported S. aureus ST121 causing sepsis (Schefold et al. 2007) , the patient received triple organism-sensitive antibiotic therapy (linezolid, imipenem and clindamycin) for 2 weeks; however, the metastatic soft tissue infection developed progressively then the antimicrobial therapy was changed to a combination of daptomycin and clindamycin. After continued antimicrobial and surgical therapy, the patient was led to stabilization and discharged from hospital on day 40. Oral antibiotic treatment with moxifloxacin was prescribed and suggested for an additional 45 days. Even though with the prolonged treatment, the outcome of infections caused by S. aureus clone ST121 largely remains unknown.
Conclusion
As a predicted founder of the major S. aureus lineages, ST121 is mainly disseminated in Africa, Asia and Europe. The overall prevalence rate was approximately 10 % in MSSA isolates, and less than 5 % in MRSA isolates. Although epidemiological data from other continents, such as Oceania and South and North America, need to be accumulated, several international studies revealed that S. aureus ST121 prevailed in these regions, such as the US (Goering et al., 2008; Rasigade et al., 2010) . Molecularly, large numbers of S. aureus ST121 isolates harbour PVL and belong to agr IV, while spa types for S. aureus ST121 strains are exceptionally diverse, with t159, t645, t314, t2304, t916, t435, t287 and t1425 as the common predominant types. These molecular characteristics reflect both the consistency and complexity of S. aureus clone ST121, facilitating the building of a surveillance strategy and monitoring system for this disseminated S. aureus clone. The disease spectrum associated with S. aureus ST121 infections is also broad. S. aureus ST121 clonal strains can be nasally carried by healthy individuals and cause mild superficial and severe invasive infections.
Although the virulence factor profile for S. aureus hypervirulent ST121 clone needs to be further investigated, the patients with ST121 infection often need longer hospitalization and need prolonged antimicrobial therapy.
